Company Analysis
Sign in

Mesoblast Limited (MESO)

Nasdaq: MESO · Biological Products, (No Diagnostic Substances) · Melbourne, Victoria, AU · filing with the SEC since 2005
Full chart Alerts Compare
Grade5.5
◀ Past 4.5● Present 5.1▶ Future 6.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$17.2M+191.4%
Net income-$102M-16.1%
Earnings per share$-0.08+5.1%
Operating cash flow-$50.0M-3.1%
Cash$162M+156.6%
Debt$122M+6.6%
Shareholders’ equity$597M+24.4%
Shares, diluted1.21B+22.4%
Return on equity-17.1%
The recordfrom its filings
Filings in 202664
Newest filingNov 12 · 6-K
Annual reportAug 27, 2026
Quarterly reportn/a
Next report due20-F by Oct 28
Insider sales, 12 months$0.00
Insider buys, 12 months$37.5M
Patents granted40
Filer categoryLarge accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton MESO · research, not advice